Silence Therapeutics Ratios (2018-2026) | SLN

Ratios Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Profitability
Gross Margin (Quarter) 82.16%-340.87%-142.92%91.95%61.97%69.50%59.75%64.71%97.39%
EBT Margin (Quarter) -13.17%-2,582.94%-2,369.49%49.90%-20,091.55%-13,672.00%-13,180.50%-37,788.24%-3,544.31%
EBIT Margin (Quarter) -35.55%-3,093.65%-2,002.47%-17.20%-20,006.34%-11,981.50%-16,505.66%166,076.47%-3,729.15%
EBITDA Margin (Quarter) -35.55%-3,093.65%-2,002.47%-17.20%-20,006.34%-11,981.50%-16,505.66%166,076.47%-3,729.15%
Operating Margin (Quarter) -35.55%-3,093.65%-2,002.47%-17.20%-20,006.34%-11,981.50%-16,505.66%166,076.47%-3,729.15%
Net Margin (Quarter) -14.73%-2,613.10%-2,372.76%48.61%-20,091.55%-13,677.00%-13,181.13%-37,788.24%-3,544.31%
FCF Margin (Quarter) -58.24%-726.72%-1,713.68%-108.84%-8,671.13%-10,916.00%-6,861.64%-50,797.06%-3,696.68%
Efficiency
Assets Average (Quarter) 390.50M457.13M428.97M307.37M179.49M159.54M193.97M175.27M156.01M139.12M123.28M
Equity Average (Quarter) 36.00M19.42M11.73M18.69M23.53M88.96M149.64M134.61M130.36M123.38M103.45M84.11M68.18M55.85M
Invested Capital (Quarter) 45.11M26.88M11.96M11.49M25.89M21.16M156.76M142.53M126.70M134.02M112.74M94.16M74.06M62.30M49.40M
Asset Utilization Ratio (Quarter) 0.270.140.150.170.000.01
Leverage & Solvency
Equity Ratio (Quarter) 0.900.450.110.090.210.180.660.610.570.500.470.43
Valuation
Enterprise Value (Quarter) -27.66M-17.38M-38.22M-99.13M-49.25M-67.99M-186.07M-136.53M-114.16M-102.19M-85.11M-70.08M
Return Ratios
Return on Sales (Quarter) 0.00%-0.26%-0.24%0.00%-2.01%-1.37%-1.32%-3.78%-0.35%
Return on Capital Employed (Quarter) -44.37%-49.31%-54.03%-59.85%-17.65%-8.40%
Return on Invested Capital (Quarter) 0.00%-0.01%-0.01%-0.01%0.00%0.00%
Return on Assets (Quarter) 0.00%0.00%0.00%0.00%0.00%0.00%0.00%-0.01%-0.01%
Return on Equity (Quarter) 0.00%0.00%0.00%0.00%-0.01%-0.01%-0.01%-0.01%-0.01%